Company Overview of Eleven Biotherapeutics, Inc.
Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its product candidates include EBI-005, a novel interleukin-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and has completed Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-031, a novel inhibitor of the cytokine interleukin-6 for the treatment of retinal dis...
215 First Street
Cambridge, MA 02142
Founded in 2008
Key Executives for Eleven Biotherapeutics, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $570.9K
Chief Financial and Business Officer
Total Annual Compensation: $429.9K
Chief Development Officer
Total Annual Compensation: $198.0K
Chief Scientific Officer
Total Annual Compensation: $402.4K
Compensation as of Fiscal Year 2014.
Eleven Biotherapeutics, Inc. Key Developments
Eleven Biotherapeutics Presents Data on EBI-031 for the Treatment of Diabetic Macular Edema
May 5 15
Eleven Biotherapeutics, Inc. announced the presentation of data for EBI-031, its novel, protein therapeutic IL-6 inhibitor in preclinical development for diabetic macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting. These preclinical pharmacokinetic studies with EBI-031, which have been optimized for intravitreal administration using Eleven’s AMP-Rx technology, confirmed the ability of EBI-031 to potently inhibit IL-6 signaling with extended vitreal retention compared to existing therapies. The Company plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) by the end of 2015 for clinical development of EBI-031 in diabetic macular edema.
Eleven Biotherapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015
Apr 30 15
Eleven Biotherapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenue of USD 24468,000 against USD 568,000 a year ago. Loss from operations was USD 7,597,000 compared to USD 7,189,000 a year ago. Net loss was USD 6,524,000 compared to USD 7,222,000 a year ago. Net loss applicable to common stockholders was USD 6,524,000 or USD 0.36 per basic and diluted share compared to USD 7,741,000 or USD 0.80 per basic and diluted share a year ago.
Eleven Announces Encouraging Data from Phase II Allergic Conjunctivitis Study
Apr 23 15
Eleven Biotherapeutics has announced encouraging data from a Phase II study of EBI-005 in patients with allergic conjunctivitis. Clinical data on Eleven's lead drug candidate, EBI-005, the first IL-1 (Interleukin-1) receptor inhibitor designed for topical ocular administration, demonstrated statistically significant improvements in ocular itching, ocular tearing and nasal symptoms associated with the late phase allergen response in patients with allergic conjunctivitis, utilizing a modified direct conjunctival allergen model. Statistically significant improvements in ocular itching (mean change from baseline) compared with vehicle were demonstrated at the final two efficacy time points (p = 0.033 at visit 6 and p = 0.046 at visit 7). Statistically significant improvements in ocular tearing (mean change from baseline) compared with vehicle were demonstrated at the final two efficacy time points (p = 0.027 at visit 6 and p = 0.044 at visit 7). Statistically significant improvements in total nasal symptoms (mean change from baseline) compared with vehicle were demonstrated at the final two efficacy time points (p = 0.004 at visit 6 and p = 0.011 at visit 7). EBI-005 was well tolerated with no treatment related serious adverse events and no evidence of drug specific antibodies.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 25, 2014